syndol film-coated tablets paracetamol 450 mg codeine phosphate hemihydrate 10 mg doxylamine succinate 5 mg caffeine 30 mg
sanofi-aventis ireland limited t/a sanofi - paracetamol; codeine phosphate hemihydrate; doxylamine succinate; caffeine - film-coated tablet - 450mg/10mg/5mg/30 milligram(s) - opioids in combination with non-opioid analgesics; codeine and paracetamol
nurofen plus tablets ibuprofen 200 mg codeine phosphate hemihydrate 12.8 mg
pco manufacturing ltd. - ibuprofen; codeine phosphate hemihydrate - film-coated tablet - 200/12.8 milligram(s) - opioids in combination with non-opioid analgesics; codeine and ibuprofen - nsaid - for the relief of pain in such conditions as: rheumatic and muscular pain, backache, migraine, dental pain, dysmenorrhoea, feverishness, symptoms of cold and flu.
solpa-plus tablets paracetamol 500 mg codeine phosphate hemihydrate 12.8 mg
chefaro ireland dac - paracetamol; codeine phosphate hemihydrate - film-coated tablet - 500 mg/12.8 milligram(s) - opioids in combination with non-opioid analgesics; codeine and paracetamol
acetaminophen and codeine phosphate tablet
redpharm drug, inc. - codeine phosphate (unii: gsl05y1mn6) (codeine anhydrous - unii:ux6owy2v7j), acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d) - acetaminophen 300 mg - acetaminophen and codeine phosphate tablets are indicated for the management of mild to moderate pain,where treatment with an opioid is appropriate and for which alternative treatments are inadequate. limitations of use because of the risks of addiction, abuse, and misuse, with opioids, even at recommended doses [see warnings], reserve acetaminophen and codeine phosphate tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics] have not provided adequate analgesia, or are not expected to provide adequate analgesia have not been tolerated, or are not expected to be tolerated acetaminophen and codeine phosphate tablets are contraindicated in patients with: patients with significant respiratory depression [see warnings]. patients with acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see warnings]. postoperative pain management in children who have undergone tonsillectomy and/or adenoidectomy [see warni
acetaminophen and codeine- acetaminophen and codeine phosphate tablet
par pharmaceutical, inc. - codeine phosphate (unii: gsl05y1mn6) (codeine anhydrous - unii:ux6owy2v7j), acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d) - codeine phosphate 30 mg - acetaminophen and codeine phosphate tablets are indicated for the management of mild to moderate pain, where treatment with an opioid is appropriate and for which alternative treatments are inadequate. limitations of use because of the risks of addiction, abuse, and misuse, with opioids, even at recommended doses [see warnings ], reserve acetaminophen and codeine phosphate tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics] - have not provided adequate analgesia, or are not expected to provide adequate analgesia, have not provided adequate analgesia, or are not expected to provide adequate analgesia, - have not been tolerated, or are not expected to be tolerated. have not been tolerated, or are not expected to be tolerated. acetaminophen and codeine phosphate tablets are contraindicated for: • all children younger than 12 years of age [see warnings ]. • post-operative management in children younger than 18 years of age following tonsillectomy and/or aden
codapane forte paracetamol 500mg and codeine phosphate hemihydrate 30mg tablet blister pack
alphapharm pty ltd - codeine phosphate hemihydrate,paracetamol -
prodeine forte paracetamol 500 mg and codeine phosphate hemihydrate 30 mg tablet blister pack
sanofi-aventis australia pty ltd - codeine phosphate hemihydrate, quantity: 30 mg; paracetamol, quantity: 500 mg - tablet, uncoated - excipient ingredients: stearic acid; maize starch; pregelatinised maize starch; povidone; magnesium stearate; purified talc; croscarmellose sodium; potassium sorbate; microcrystalline cellulose - prodeine forte is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.
panamax co paracetamol 500 mg and codeine phosphate hemihydrate 8 mg tablet blister pack
sanofi-aventis australia pty ltd - codeine phosphate hemihydrate, quantity: 8 mg; paracetamol, quantity: 500 mg - tablet, uncoated - excipient ingredients: soluble maize starch; povidone; microcrystalline cellulose; stearic acid; potassium sorbate; magnesium stearate; maize starch; purified talc - for the relief of acute moderate pain
brufen plus 200/12.8 ibuprofen 200 mg and codeine phosphate hemihydrate 12.8 mg tablet blister pack
viatris pty ltd - codeine phosphate hemihydrate, quantity: 12.8 mg; ibuprofen, quantity: 200 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; colloidal anhydrous silica; pregelatinised maize starch; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 400 - for the temporary relief of acute moderate pain and inflammation
acetaminophen and codeine phosphate tablet
direct_rx - codeine phosphate (unii: gsl05y1mn6) (codeine anhydrous - unii:ux6owy2v7j), acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d) - acetaminophen and codeine phosphate tablets are indicated for the management of mild to moderate pain,where treatment with an opioid is appropriate and for which alternative treatments are inadequate. limitations of use because of the risks of addiction, abuse, and misuse, with opioids, even at recommended doses [see warnings], reserve acetaminophen and codeine phosphate tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics] •have not provided adequate analgesia, or are not expected to provide adequate analgesia •have not been tolerated, or are not expected to be tolerated acetaminophen and codeine phosphate tablets are contraindicated for: all children younger than 12 years of age (see warnings). post-operative management in children younger than 18 years of age following tonsillectomy and/or adenoidectomy (see warnings). acetaminophen and codeine phosphate tablets are contraindicated in patients with: significant respiratory depression [seewarnings].